BioAge Labs CFO exercises 3,542 stock options

BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein exercised stock options for 3,542 shares of common stock at $4.38 per share.

Rhea-AI Filing Summary

BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein exercised stock options for 3,542 shares of common stock at $4.38 per share. Following the exercise, he directly holds 36,575 common shares and 155,833 stock options, which vest in equal monthly installments through their February 17, 2035 expiration.

Insider Trade Summary

3,542 shares exercised/converted

Exercise 2 txns

Insider GOLDSTEIN DOV A MD

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,542	$0.00	$0.00
Exercise	Common Stock	3,542	$4.38	$16K

Holdings After Transaction: Stock Option (Right to Buy) — 155,833 contracts (Direct); Common Stock — 36,575 shares (Direct)

Footnotes (1)

1. F1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options Exercised: 3,542 shares Exercise Price: $4.38 per share Common Shares Held: 36,575 shares +3 more

6 metrics

Options Exercised 3,542 shares Common stock acquired via option exercise on 2026-04-23

Exercise Price $4.38 per share Strike price of exercised stock options

Common Shares Held 36,575 shares Direct common stock ownership after transaction

Options Remaining 155,833 options Stock options held after transaction

Option Expiration February 17, 2035 Expiration date of the stock option grant

Vesting Schedule 1/48 monthly Award vests monthly starting February 1, 2025

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, Chief Financial Officer

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for derivative transaction"

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vesting financial

"The option vested or vests as to 1/48th of the total award monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Chief Financial Officer financial

"officer_title: "Chief Financial Officer" for reporting person"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioAge Labs (BIOA) CFO Dov Goldstein do in this Form 4?

BioAge Labs CFO Dov A. Goldstein exercised stock options to acquire 3,542 shares of common stock at $4.38 per share. This was an option exercise, not an open-market purchase, and reflects compensation becoming actual share ownership under his equity award.

How many BioAge Labs (BIOA) shares does the CFO own after this transaction?

After the option exercise, Dov Goldstein directly holds 36,575 shares of BioAge Labs common stock. He also continues to hold 155,833 stock options, giving him additional potential equity exposure if those options vest and are exercised in the future.

What are the key terms of the BioAge Labs (BIOA) stock options exercised?

The exercised stock options allowed purchase of 3,542 shares at $4.38 per share and expire on February 17, 2035. The award vests monthly in forty‑eight equal installments, starting February 1, 2025, contingent on continued service with BioAge Labs at each vesting date.

Was this BioAge Labs (BIOA) CFO transaction a market buy or a routine option exercise?

This transaction was a routine option exercise, coded “M” as an exercise or conversion of a derivative security. Goldstein converted 3,542 stock options into common shares at the preset $4.38 price, rather than buying shares on the open market.

How many BioAge Labs (BIOA) stock options does the CFO hold after this exercise?

Following the exercise of 3,542 options, Dov Goldstein holds 155,833 stock options. These options relate to BioAge Labs common stock and continue vesting monthly, with the option grant scheduled to expire on February 17, 2035, if not fully exercised before then.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSTEIN DOV A MD

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		M		3,542	A	$4.38	36,575	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.38	04/23/2026		M			3,542	(1)	02/17/2035	Common Stock	3,542	$0	155,833	D

Explanation of Responses:

1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)